Literature DB >> 7985891

Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death.

J G Clark1, J A Milberg, K P Steinberg, L D Hudson.   

Abstract

OBJECTIVE: To determine whether bronchoalveolar lavage fluid levels of the N-terminal peptide of type III procollagen (procollagen III) are increased in patients with the adult respiratory distress syndrome and, if so, whether increased procollagen III levels in lavage fluid are associated with increased fatality rates.
DESIGN: Prospective cohort study.
SETTING: Intensive care units of a tertiary care hospital affiliated with a medical school. PATIENTS: 117 consecutive patients with the adult respiratory distress syndrome prospectively identified on admission; 6 healthy volunteers served as controls. MEASUREMENTS: Bronchoalveolar lavage fluid procollagen III levels in 117 patients at 3, 7, and 14 days after onset of the adult respiratory distress syndrome (total of 196 lavage samples).
RESULTS: The median procollagen III level was 1.75 U/mL (range, 0 to 13.4 U/mL) in lavage fluid obtained from patients with the adult respiratory distress syndrome. We detected procollagen III levels in lavage fluid from 80% of patients (94 of 117) but not in 6 normal volunteers. The overall fatality rate was 41% (48 of 117 patients). In a univariate analysis, the relative risk (RR) for death was increased in patients with procollagen III levels of 1.75 U/mL or more obtained on day 3 (RR, 2.4; 95% CI, 1.3 to 4.3), day 7 (RR, 2.7; CI, 1.4 to 5.4), and day 14 (RR, 2.7; CI, 1.1 to 6.3). Inclusion of other variables in a multivariate model only minimally decreased the risk associated with increased procollagen III levels.
CONCLUSION: Increased levels of type III procollagen in bronchoalveolar lavage fluid are frequently detected in patients with the adult respiratory distress syndrome and are strongly associated with increased risk for fatal outcome independent of other variables related to fatality in patients with the syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7985891     DOI: 10.7326/0003-4819-122-1-199501010-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  60 in total

Review 1.  The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology.

Authors:  K Atabai; M A Matthay
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

2.  Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome.

Authors:  Jeffrey C Horowitz; Zongbin Cui; Thomas A Moore; Tamara R Meier; Raju C Reddy; Galen B Toews; Theodore J Standiford; Victor J Thannickal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-10-07       Impact factor: 5.464

Review 3.  Microarray-based analysis of ventilator-induced lung injury.

Authors:  Mark M Wurfel
Journal:  Proc Am Thorac Soc       Date:  2007-01

4.  Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury.

Authors:  Lynn M Schnapp; Samuel Donohoe; Jinzhi Chen; Donald A Sunde; Patricia M Kelly; John Ruzinski; Thomas Martin; David R Goodlett
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

5.  SARS-CoV regulates immune function-related gene expression in human monocytic cells.

Authors:  Wanchung Hu; Yu-Ting Yen; Sher Singh; Chuan-Liang Kao; Betty A Wu-Hsieh
Journal:  Viral Immunol       Date:  2012-08       Impact factor: 2.257

6.  Beyond mortality: future clinical research in acute lung injury.

Authors:  Roger G Spragg; Gordon R Bernard; William Checkley; J Randall Curtis; Ognjen Gajic; Gordon Guyatt; Jesse Hall; Elliott Israel; Manu Jain; Dale M Needham; Adrienne G Randolph; Gordon D Rubenfeld; David Schoenfeld; B Taylor Thompson; Lorraine B Ware; Duncan Young; Andrea L Harabin
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

7.  Gene expression changes during the development of acute lung injury: role of transforming growth factor beta.

Authors:  Scott C Wesselkamper; Lisa M Case; Lisa N Henning; Michael T Borchers; Jay W Tichelaar; John M Mason; Nadine Dragin; Mario Medvedovic; Maureen A Sartor; Craig R Tomlinson; George D Leikauf
Journal:  Am J Respir Crit Care Med       Date:  2005-08-11       Impact factor: 21.405

8.  Biology and pathology of fibroproliferation following the acute respiratory distress syndrome.

Authors:  Carolyn M Hendrickson; Bruno Crestani; Michael A Matthay
Journal:  Intensive Care Med       Date:  2014-12-06       Impact factor: 17.440

Review 9.  The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance.

Authors:  Ellen L Burnham; William J Janssen; David W H Riches; Marc Moss; Gregory P Downey
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

10.  Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs.

Authors:  Raphael Briot; Sam Bayat; Daniel Anglade; Jean-Louis Martiel; Francis Grimbert
Journal:  Crit Care       Date:  2009-10-21       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.